Sub-Total: $0.00 CAD
Master Dosage Chart
Knowledge · Master Dosage Chart
Every catalogue compound,on one screen.
Common reconstitution, the amount range reported for it, and how much human evidence sits behind that range. Sort any column. The evidence label is the most important thing on the row.
ShowClick any column heading to sort
| Compound | Vial | Type | Common reconstitution | Reported amount | Frequency | Evidence |
|---|---|---|---|---|---|---|
| BPC-157 | 10 mg | Single | 2 mL → 5 mg/mL | 200–500 mcg | Daily / twice daily | Limited human data |
| TB-500 | 10 mg | Single | 2 mL → 5 mg/mL | 2–5 mg per week | 1–2× weekly | Preclinical only |
| GHK-Cu | 50 mg | Single | 3 mL → 16.7 mg/mL | 1–2 mg | Daily–3× weekly | Limited human data |
| Retatrutide | 10 mg | Single | 1 mL → 10 mg/mL | 2–12 mg (trial doses) | Once weekly | Human trial data |
| Retatrutide | 20 mg | Single | 2 mL → 10 mg/mL | 2–12 mg (trial doses) | Once weekly | Human trial data |
| Tesamorelin | 20 mg | Single | 4 mL → 5 mg/mL | 2 mg (approved dose) | Once daily | Human trial data |
| Ipamorelin | 10 mg | Single | 2 mL → 5 mg/mL | 200–300 mcg | 1–3× daily | Limited human data |
| CJC-1295 no DAC | 10 mg | Single | 2 mL → 5 mg/mL | 100–200 mcg | 1–3× daily | Limited human data |
| MOTS-c | 10 mg | Single | 2 mL → 5 mg/mL | 5–10 mg per week | 2–3× weekly | Limited human data |
| NAD+ | 500 mg | Single | 5 mL → 100 mg/mL | 50–100 mg | Daily–weekly | Limited human data |
| SS-31 | 10 mg | Single | 2 mL → 5 mg/mL | 5–10 mg | Daily | Human trial data |
| Epitalon | 10 mg | Single | 2 mL → 5 mg/mL | 5–10 mg | Daily, 10–20 day course | Preclinical only |
| Semax | 10 mg | Single | 2 mL → 5 mg/mL | 300–600 mcg | Daily, intranasal in trials | Limited human data |
| Selank | 10 mg | Single | 2 mL → 5 mg/mL | 250–500 mcg | Daily, intranasal in trials | Preclinical only |
| DSIP | 10 mg | Single | 2 mL → 5 mg/mL | 100–300 mcg | Evening | Preclinical only |
| PT-141 | 10 mg | Single | 2 mL → 5 mg/mL | 0.5–1.75 mg (approved 1.75 mg) | As needed | Human trial data |
| Melanotan II | 10 mg | Single | 2 mL → 5 mg/mL | 250–500 mcg | Loading then maintenance | Limited human data |
| AOD-9604 | 5 mg | Single | 2 mL → 2.5 mg/mL | 300 mcg | Daily | Limited human data |
| 5-Amino-1MQ | 10 mg | Single | 2 mL → 5 mg/mL | 50–150 mg oral in studies | Daily | Preclinical only |
| Cartalax | 20 mg | Single | 2 mL → 10 mg/mL | 1–2 mg | Daily, 10–20 day course | Preclinical only |
| Wolverine | 20 mg | Blend | 2 mL → 10 mg/mL | 1:1 BPC-157 : TB-500 | See profile | Preclinical only |
| GLOW | 70 mg | Blend | 3 mL → 23.3 mg/mL | Split across 3 components | See profile | Preclinical only |
| KLOW | 80 mg | Blend | 3 mL → 26.7 mg/mL | Split across 4 components | See profile | Preclinical only |
23 rows. 5 of them carry human trial data; the rest are labelled for exactly what they are. Reconstitution volumes are the common convention, not an instruction — the calculator will work out any other volume you choose.
Read the evidence column before the amount column. “Limited human data” and “Preclinical only” figures are vendor and community convention. They have not been validated in humans and should not be read as equivalent to a trial-backed dose, however precise the number looks. For laboratory research use only — not for human or veterinary use.